Literature DB >> 33300217

A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.

Yusuke Taira1, Yuko Shimoji1, Tadaharu Nakasone1, Yoshihisa Arakaki1, Tomoko Nakamoto1, Wataru Kudaka1, Yoichi Aoki1.   

Abstract

Nasal septal perforation caused by bevacizumab is rarely reported in other cancers such as ovarian cancer and breast cancer, but it has not been reported in cervical cancer. A 48-year-old woman with a medical history of chronic allergic rhinitis was diagnosed stage 4B (T2bN1M0) cervical cancer and paclitaxel and carboplatin along with bevacizumab (triweekly) were administered. After eight courses of chemotherapy, nasal septal perforation was noted. The possibility of nasal septal perforation by bevacizumab was considered by excluding other causes. We report the first case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.
© 2020 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  bevacizumab; cervical cancer; nasal septal perforation

Mesh:

Substances:

Year:  2020        PMID: 33300217     DOI: 10.1111/jog.14589

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  2 in total

1.  Perforation of the Nasal Septum in a Colorectal Cancer Patient Treated With Aflibercept: A Case Report.

Authors:  Javier David Benitez Fuentes; Alfonso Lopez de Sa Lorenzo; Alberto Elpidio Calvo Elias; Carmen Toledano Rojas; Monica Granja Ortega
Journal:  Cureus       Date:  2022-07-12

2.  Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions.

Authors:  Jiangfeng Wang; Qiang Zhao; Lei Cai; Jianqiang Li; Sheng Chen
Journal:  Biomed Res Int       Date:  2022-04-18       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.